Liquid biopsy in lung cancer

A perspective from members of the pulmonary pathology society

Lynette M. Sholl, Dara L. Aisner, Timothy Craig Allen, Mary Beth Beasley, Philip T. Cagle, Vera L. Capelozzi, Sanja Dacic, Lida P. Hariri, Keith M. Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Eric Thunnissen, Ming Tsao, Marina Vivero, Yasushi Yatabe

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction- and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology. In fact, the US Food and Drug Administration has approved one circulating tumor cell selection platform, the CellSearch System. Although the use of liquid biopsy in a patient population with a genomically defined solid tumor may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis of lung cancer. Liquid biopsy has not been validated for lung cancer diagnosis, and its lower sensitivity could lead to significant diagnostic delay if liquid biopsy were to be used in lieu of tissue biopsy. Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven.

Original languageEnglish (US)
Pages (from-to)825-829
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume140
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Lung Neoplasms
Pathology
Biopsy
Lung
Circulating Neoplastic Cells
RNA
Neoplasms
United States Food and Drug Administration
Technology
Equipment and Supplies
Polymerase Chain Reaction
Population
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)
  • Medical Laboratory Technology

Cite this

Sholl, L. M., Aisner, D. L., Allen, T. C., Beasley, M. B., Cagle, P. T., Capelozzi, V. L., ... Yatabe, Y. (2016). Liquid biopsy in lung cancer: A perspective from members of the pulmonary pathology society. Archives of Pathology and Laboratory Medicine, 140(8), 825-829. https://doi.org/10.5858/arpa.2016-0163-SA

Liquid biopsy in lung cancer : A perspective from members of the pulmonary pathology society. / Sholl, Lynette M.; Aisner, Dara L.; Allen, Timothy Craig; Beasley, Mary Beth; Cagle, Philip T.; Capelozzi, Vera L.; Dacic, Sanja; Hariri, Lida P.; Kerr, Keith M.; Lantuejoul, Sylvie; Mino-Kenudson, Mari; Raparia, Kirtee; Rekhtman, Natasha; Roy-Chowdhuri, Sinchita; Thunnissen, Eric; Tsao, Ming; Vivero, Marina; Yatabe, Yasushi.

In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 8, 01.08.2016, p. 825-829.

Research output: Contribution to journalReview article

Sholl, LM, Aisner, DL, Allen, TC, Beasley, MB, Cagle, PT, Capelozzi, VL, Dacic, S, Hariri, LP, Kerr, KM, Lantuejoul, S, Mino-Kenudson, M, Raparia, K, Rekhtman, N, Roy-Chowdhuri, S, Thunnissen, E, Tsao, M, Vivero, M & Yatabe, Y 2016, 'Liquid biopsy in lung cancer: A perspective from members of the pulmonary pathology society', Archives of Pathology and Laboratory Medicine, vol. 140, no. 8, pp. 825-829. https://doi.org/10.5858/arpa.2016-0163-SA
Sholl, Lynette M. ; Aisner, Dara L. ; Allen, Timothy Craig ; Beasley, Mary Beth ; Cagle, Philip T. ; Capelozzi, Vera L. ; Dacic, Sanja ; Hariri, Lida P. ; Kerr, Keith M. ; Lantuejoul, Sylvie ; Mino-Kenudson, Mari ; Raparia, Kirtee ; Rekhtman, Natasha ; Roy-Chowdhuri, Sinchita ; Thunnissen, Eric ; Tsao, Ming ; Vivero, Marina ; Yatabe, Yasushi. / Liquid biopsy in lung cancer : A perspective from members of the pulmonary pathology society. In: Archives of Pathology and Laboratory Medicine. 2016 ; Vol. 140, No. 8. pp. 825-829.
@article{ed32168a9f4443498102c9522a63233e,
title = "Liquid biopsy in lung cancer: A perspective from members of the pulmonary pathology society",
abstract = "Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction- and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology. In fact, the US Food and Drug Administration has approved one circulating tumor cell selection platform, the CellSearch System. Although the use of liquid biopsy in a patient population with a genomically defined solid tumor may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis of lung cancer. Liquid biopsy has not been validated for lung cancer diagnosis, and its lower sensitivity could lead to significant diagnostic delay if liquid biopsy were to be used in lieu of tissue biopsy. Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven.",
author = "Sholl, {Lynette M.} and Aisner, {Dara L.} and Allen, {Timothy Craig} and Beasley, {Mary Beth} and Cagle, {Philip T.} and Capelozzi, {Vera L.} and Sanja Dacic and Hariri, {Lida P.} and Kerr, {Keith M.} and Sylvie Lantuejoul and Mari Mino-Kenudson and Kirtee Raparia and Natasha Rekhtman and Sinchita Roy-Chowdhuri and Eric Thunnissen and Ming Tsao and Marina Vivero and Yasushi Yatabe",
year = "2016",
month = "8",
day = "1",
doi = "10.5858/arpa.2016-0163-SA",
language = "English (US)",
volume = "140",
pages = "825--829",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "8",

}

TY - JOUR

T1 - Liquid biopsy in lung cancer

T2 - A perspective from members of the pulmonary pathology society

AU - Sholl, Lynette M.

AU - Aisner, Dara L.

AU - Allen, Timothy Craig

AU - Beasley, Mary Beth

AU - Cagle, Philip T.

AU - Capelozzi, Vera L.

AU - Dacic, Sanja

AU - Hariri, Lida P.

AU - Kerr, Keith M.

AU - Lantuejoul, Sylvie

AU - Mino-Kenudson, Mari

AU - Raparia, Kirtee

AU - Rekhtman, Natasha

AU - Roy-Chowdhuri, Sinchita

AU - Thunnissen, Eric

AU - Tsao, Ming

AU - Vivero, Marina

AU - Yatabe, Yasushi

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction- and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology. In fact, the US Food and Drug Administration has approved one circulating tumor cell selection platform, the CellSearch System. Although the use of liquid biopsy in a patient population with a genomically defined solid tumor may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis of lung cancer. Liquid biopsy has not been validated for lung cancer diagnosis, and its lower sensitivity could lead to significant diagnostic delay if liquid biopsy were to be used in lieu of tissue biopsy. Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven.

AB - Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction- and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology. In fact, the US Food and Drug Administration has approved one circulating tumor cell selection platform, the CellSearch System. Although the use of liquid biopsy in a patient population with a genomically defined solid tumor may potentially be clinically useful, it currently does not supersede conventional pretreatment tissue diagnosis of lung cancer. Liquid biopsy has not been validated for lung cancer diagnosis, and its lower sensitivity could lead to significant diagnostic delay if liquid biopsy were to be used in lieu of tissue biopsy. Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven.

UR - http://www.scopus.com/inward/record.url?scp=84980332141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980332141&partnerID=8YFLogxK

U2 - 10.5858/arpa.2016-0163-SA

DO - 10.5858/arpa.2016-0163-SA

M3 - Review article

VL - 140

SP - 825

EP - 829

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 8

ER -